Kidney Cancer | Tumor

Frontline Treatment Options for Stage 4 RCC

June 24th 2019

Advice for Patients with RCC Choosing a Treatment Option

June 24th 2019

The Diagnosis of a Patient with Stage 4 Renal Cell Cancer

June 24th 2019

Despite Advantages, Disparities in Access to Palliative Care in Kidney Cancer Remain

June 19th 2019

Although palliative care has been shown to improve survival rates among patients with metastatic renal cell carcinoma, its utilization remains low while certain barriers and disparities still exist.

Novel 'Theranostic' Screening Tool Shows Promise in Determining Kidney Cancer Treatment

June 17th 2019

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

Survey Results Highlight Unmet Needs of Patients with Kidney Cancer Worldwide

June 13th 2019

An international study of nearly 2,000 patients with renal cell carcinoma exposed many unmet needs across all stages of disease.

Immunotherapy Combinations Transform Renal Cell Carcinoma Treatment

May 22nd 2019

Patients with advanced renal cell carcinoma have new first-line therapy options.

FDA Approves Bavencio-Inlyta Combo for Advanced Renal Cell Carcinoma

May 15th 2019

The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.

Yervoy Plus Opdivo Appears to be a Cost-Effective Treatment Option in Kidney Cancer

May 10th 2019

With the growing price of cancer treatment, researchers evaluated the cost-effectiveness of the new standard-of-care in frontline metastatic renal cell carcinoma.

Findings Confirm Exercise Benefit for Kidney Cancer Survivors

May 9th 2019

Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.

Immunotherapy Combinations Show Promise in Frontline Setting for Advanced Kidney Cancer

April 29th 2019

With patient resistance to single-agent immunotherapies in the treatment of advanced renal cell carcinoma, new combination therapies are needed in the frontline setting.

The Role of Mental Health in Cancer Outcomes

April 24th 2019

A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.

FDA Approves Keytruda in Combination with Inlyta for Frontline Renal Cell Carcinoma

April 22nd 2019

The Food and Drug Administration approved Keytruda in combination with Inlyta for the frontline treatment of patients with advanced renal cell carcinoma.

Keytruda Combo Improves Survival in Advanced Renal Cell Carcinoma

April 19th 2019

The combination use of Keytruda plus Inlyta significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma – the most common type of kidney cancer.

Expert Discusses Molecular Diagnosis of Renal Cell Carcinoma

March 25th 2019

There is still work to do in the field of molecular diagnosis for renal cell carcinoma, according to David I. Quinn, MBBS, Ph.D., FRACP, FACP.

Thanks to Immunotherapies, the Outlook for Patients with RCC is Changing

March 25th 2019

An expert discusses the evolving treatments for renal cell carcinoma (RCC) over the last decade, as well as the future role of immunotherapies for patients with RCC.

Kidney Cancer: Know the Risk Factors

March 11th 2019

In conjunction with Kidney Cancer Awareness Month, learn more about risk factors and treatment options for the disease.

How One Survivor 'Keeps On Keeping On'

March 7th 2019

In this week’s episode, we spoke with a patient advocate and survivor of renal cell carcinoma to help raise awareness during Kidney Cancer Awareness month.

Bavencio-Inlyta Combination Shows Promise Across Subtypes of Renal Cell Carcinoma

March 6th 2019

Frontline use of Bavencio (avelumab) plus Inlyta (axitinib) significantly improved progression-free survival compared with the standard of care in patients with advanced renal cell carcinoma.

Rising Cancer Incidence Trends in Millennials Partially Attributed to Climbing Obesity Rates

February 25th 2019

CURE® spoke with a researcher from the American Cancer Society to examine temporal trends of obesity-related cancers in younger adults.

FDA Grants Priority Review to Keytruda Combo as Frontline Treatment for Kidney Cancer

February 15th 2019

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma.

FDA Grants Priority Review to Bavencio Plus Inlyta to Treat Advanced Renal Cell Carcinoma

February 12th 2019

The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).

Aerobics, Strength Exercises Improve Quality of Life in Kidney Cancer Survivors

January 28th 2019

Meeting combined exercise guidelines improved quality of life in kidney cancer survivors; however, few individuals reported that they actually follow such guidelines.

Immunotherapy Pair Good for Some, Not All, With Kidney Cancer

January 25th 2019

Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.

Obesity Factors May Increase Kidney Cancer Risk

January 25th 2019

Certain factors – such as diastolic blood pressure and fasting insulin – were found to be associated with renal cell carcinoma.

Occupational Gasoline Exposure May Increase Kidney Cancer Risk

January 15th 2019

People who have experienced high exposures to gasoline might be at an increased risk for kidney cancer, according to recent research.

Staying Vigilant to Manage Treatment-Related Side Effects in Kidney Cancer

January 14th 2019

Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.

Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy

January 10th 2019

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

Fotivda Lengthens Time to Disease Progression in Renal Cell Carcinoma

November 19th 2018

The phase 3 TIVO-3 trial – designed to evaluate the efficacy of Fotivda in patients with renal cell carcinoma – met its primary endpoint of improved progression-free survival.

CURE New Issue Alert: Fall 2018

November 14th 2018

We've got a sneak peek at what’s inside our Fall 2018 issue.